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Nutraceutical and pharmaceutical cocktails did not improve muscle function or 
reduce histological damage in D2-mdx mice 
Abstract 
Progressive muscle injury and weakness are hallmarks of Duchenne muscular dystrophy. We showed 
previously that quercetin (Q) partially protected dystrophic limb muscles from disease-related injury. As 
quercetin activates PGC-1α through Sirtuin-1, an NAD+-dependent deacetylase, the depleted NAD+ in 
dystrophic skeletal muscle may limit quercetin efficacy, hence, supplementation with the NAD+ donor, 
nicotinamide riboside (NR), may facilitate quercetin efficacy. Lisinopril (Lis) protects skeletal muscle and 
improves cardiac function in dystrophin-deficient mice, therefore it was included in this study to evaluate 
the effects of lisinopril used with quercetin and NR. Our purpose was to determine the extent to which Q, 
NR, and Lis decreased dystrophic injury. We hypothesized that Q, NR or Lis alone would improve muscle 
function and decrease histological injury and when used in combination would have additive effects. 
Muscle function of 11-month-old DBA (healthy), D2-mdx (dystrophin-deficient), and D2-mdx mice was 
assessed following treatment with Q, NR, and/or Lis for 7-months. To mimic typical pharmacology of 
DMD patients a group was treated with prednisolone (Pred) in combination with Q, NR and Lis. At 
11-months of age, dystrophin deficiency decreased specific tension and tetanic force in the soleus and 
extensor digitorum longus muscles and was not corrected by any treatment. Dystrophic muscle was more 
sensitive to contraction-induced injury, which was partially offset in the QNRLisPred group, while fatigue 
was similar between all groups. Treatments did not decrease histological damage. These data suggest 
treatment with Q, NR, Lis and Pred failed to adequately maintain dystrophic limb muscle function or 
decrease histological 46 damage. 
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Progressive muscle injury and weakness are hallmarks of Duchenne muscular 26 
dystrophy. We showed previously that quercetin (Q) partially protected dystrophic limb 27 
muscles from disease-related injury. As quercetin activates PGC-1α through Sirtuin-1, an 28 
NAD+-dependent deacetylase, the depleted NAD+ in dystrophic skeletal muscle may limit 29 
quercetin efficacy, hence, supplementation with the NAD+ donor, nicotinamide riboside 30 
(NR), may facilitate quercetin efficacy. Lisinopril (Lis) protects skeletal muscle and 31 
improves cardiac function in dystrophin-deficient mice, therefore it was included in this 32 
study to evaluate the effects of lisinopril used with quercetin and NR.  Our purpose was to 33 
determine the extent to which Q, NR, and Lis decreased dystrophic injury. We hypothesized 34 
that Q, NR or Lis alone would improve muscle function and decrease histological injury and 35 
when used in combination would have additive effects.  Muscle function of 11-month-old 36 
DBA (healthy), D2-mdx (dystrophin-deficient), and D2-mdx mice was assessed following 37 
treatment with Q, NR, and/or Lis for 7-months. To mimic typical pharmacology of DMD 38 
patients a group was treated with prednisolone (Pred) in combination with Q, NR and Lis. At 39 
11-months of age, dystrophin deficiency decreased specific tension and tetanic force in the 40 
soleus and extensor digitorum longus muscles and was not corrected by any treatment.  41 
Dystrophic muscle was more sensitive to contraction-induced injury, which was partially 42 
offset in the QNRLisPred group, while fatigue was similar between all groups. Treatments 43 
did not decrease histological damage. These data suggest treatment with Q, NR, Lis and Pred 44 
failed to adequately maintain dystrophic limb muscle function or decrease histological 45 
damage. 46 
Keywords: DMD, prednisolone, glucocorticoid, ACE inhibitor, quercetin  47 
New and Noteworthy 48 
Despite a compelling rationale and previous evidence to the contrary in short-term 49 
investigations, quercetin, nicotinamide riboside, or Lisinopril, alone or in combination, failed 50 
to restore muscle function or decrease histological injury in dystrophic limb muscle from D2-51 
mdx mice following long-term administration.  Importantly, we also found that in the D2-52 
mdx model, an emerging and relatively understudied model of DMD, dystrophin deficiency 53 
caused profound muscle dysfunction and histopathology in skeletal muscle.   54 
  55 
Introduction 56 
 Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disease caused 57 
by a mutation in the dystrophin gene resulting in dystrophin protein deficiency. By the age of 58 
twelve, children with DMD are usually wheelchair bound and will typically succumb to the 59 
disease in their 3rd decade of life due to respiratory or cardiac failure (13). In addition to 60 
muscle fragility, dystrophin deficiency results in a host of cellular dysfunctions including, but 61 
not limited to, impaired autophagy, calcium mishandling, oxidative stress, and mitochondrial 62 
dysfunction (4, 20, 29). Collectively, this structural injury and cellular dysfunction results in 63 
histopathologic changes including immune cell infiltration, fibrosis, increased necrotic area, 64 
increased fatty infiltration, and a reduction in contractile tissue (5, 17). 65 
Transgenic or vector-mediated overexpression of PGC-1α reduced histological 66 
damage and preserved muscle function in dystrophic skeletal muscle (9, 16, 17, 27). We have 67 
pursued the capacity of quercetin, a natural flavonoid with anti-oxidant and anti-68 
inflammatory properties (1, 6, 11), to attenuate disease severity as it drives PGC-1α activity 69 
through Sirtuin 1 (SIRT1), an NAD+-dependent deacetylase (12, 22).  We discovered 70 
previously that six months of oral quercetin delivery decreased histopathological injury in 71 
dystrophic diaphragms and hearts of mdx mice (3, 18), however, long-term administration of 72 
quercetin transiently maintained respiratory function and modestly protected limb muscles, 73 
while in corresponding hearts indices of inflammation were reduced and markers of 74 
mitochondrial biogenesis were increased (2, 26, 28). 75 
As quercetin relies on SIRT1 activity to drive signaling, we proposed that limited 76 
NAD+ in dystrophic muscle (8) may hinder the efficacy of quercetin (28) and that 77 
supplementation with nicotinamide riboside (NR), an NAD+ precursor, would maintain 78 
quercetin-mediated elevations in SIRT1 activity, PGC-1α activity, and muscle function.  79 
Indeed, it was recently demonstrated that muscle function was improved following 12 weeks 80 
of NR supplementation (25). Independent of quercetin, early intervention with angiotensin-81 
converting enzyme (ACE) inhibitor, Lisinopril (Lis), improved histological injury (21) and in 82 
combination with aldosterone receptor antagonist, spironolactone, improved function and 83 
reduced histological damage of dystrophic cardiac and skeletal muscle (19, 23). Conversely, 84 
it appears that activation of aldosterone receptors on muscle fibers can potentiate muscle 85 
injury (7). As quercetin and Lisinopril appear to operate through independent mechanisms it 86 
may provide an opportunity for additive or even synergistic therapeutic benefits. The goal of 87 
this investigation was to determine the extent to which NR and/or Lis would augment 88 
therapeutic effects of quercetin on disease severity in dystrophic limb muscles.  We 89 
hypothesized that the oral administration of quercetin in combination with NR and/or Lis 90 
would improve muscle function and decrease histological injury in dystrophic muscle 91 
compared to untreated dystrophic muscle.   92 
  93 
Methods 94 
Animal Treatments. All animal procedures were approved by the Institutional Animal 95 
Care and Use Committees at University of Montana (047-16JQHHP-072616) and the 96 
University of Florida (201508822). In this investigation we utilized an emerging model of 97 
DMD, the D2-mdx mouse (D2.B10-Dmdmdx/J), which was produced by crossing the 98 
traditional BL10-mdx mouse onto the DBA background such that dystrophin deficiency is 99 
caused by the identical nonsense mutation in exon 23 of the dystrophin gene. The DBA 100 
background has a 12-amino acid deletion in the latent TGF-β-binding protein gene 4 (Ltbp4).  101 
Similar mutations have been linked to accelerated losses of ambulation in DMD patients (10, 102 
14). Additionally, the DBA background has a mutation in the Anxa6 gene leading to the 103 
truncation of annexin A6 protein, which is involved in satellite cell self-renewal and 104 
membrane repair (30). The DBA background provides a more severe phenotype resulting in 105 
increased fibrosis, increased muscle damage, and decreased regenerative capacity in the D2-106 
mdx mouse (10, 15, 24).  We chose this model precisely because disease severity more 107 
closely recapitulates disease severity in DMD patients than the conventional mdx model with 108 
the hope that results using D2-mdx mice would be more predictive of outcomes (positive or 109 
negative) in DMD patients.  Ten male DBA2/J (DBA; control) mice and 80 male D2.B10-110 
Dmdmdx/J (D2-mdx; dystrophin deficient) mice were obtained from Jackson Laboratory (Bar 111 
Harbor, ME).  Following an acclimation period of at least one week, 4 month old mice were 112 
assigned to nine groups (n=10/group): DBA, untreated D2-mdx, and D2-mdx treated with 113 
quercetin (Q, 0.2% by diet, 275 mg/kg/d), nicotinamide riboside (NR, 0.04% by diet, 55 114 
mg/kg/d ), Q and NR (QNR), Lisinopril (Lis, 33 mg/L in water, 9.15 ng/kg/d), Q and Lis 115 
(QLis), QNRLis, or  QNRLis + prednisolone (QNRLisPred, 10 mg/L by water, 2.77 116 
mg/kg/d). The QNRLisPred group was included to test the most complete cocktail (QNRLis) 117 
in the context of common pharmacology used to treated DMD patients. Treatments were 118 
initiated at 4 months of age to demonstrate the efficacy of these treatments using a rescue 119 
paradigm, which more closely replicates the onset of treatment for DMD patients. All 120 
animals were given access to food and water ad libitum regardless of treatment. Caregivers 121 
and technicians were blinded to animal treatment and treatment groups were assigned 122 
numbers to ensure blinded conditions throughout data collection. Following 7 months of 123 
treatment soleus and extensor digitorum longus (EDL) were collected.   124 
Muscle function.  In vitro muscle function was assessed in the soleus and EDL at the 125 
University of Florida Myology Institute Physiological Assessment Core as previously 126 
described (28, 31). Briefly, soleus and EDL muscles were removed following surgical 127 
sedation with ketamine and xylazine and placed in a bath of oxygenated Ringers solution 128 
(120mM NaCl, 4.7mM KCl, 2.5mM CaCl2, 1.2mM KH2PO4, 1.2mM MgSO4, 25mM HEPES 129 
and 5.5mM Glucose). Isometric tetanic force was measured at 120 Hz and 100 Hz for EDL 130 
and soleus, respectively. To determine fatigue resistance, the soleus was stimulated with 1 131 
contraction/sec at 100Hz for 330 msec with 200 μsec pulses for 10 min. Fatigue resistance 132 
was reported as percentage of remaining initial force. Finally, to assess resistance to 133 
contraction-induced injury, five lengthening contractions of 500 msec duration at 80 Hz 134 
followed by a final 10% stretch beyond Lo for 200 msec were applied to EDL muscles.  135 
Resistance to contraction-induce injury was reported as percent of initial force production.   136 
Histology.  Muscle damage and fibrotic area were assessed using hematoxylin & 137 
eosin (H&E) and Masson’s Trichrome (KTMTRPT, American MasterTech, Lodi, CA) 138 
staining as previously described (26, 28). Soleus and EDL muscles were coated in OCT and 139 
frozen for histology in liquid nitrogen-chilled isopentane. Briefly, 10 μm sections were 140 
stained with H&E or Masson’s Trichrome, and imaged at 10x and 40x magnification by a 141 
blinded, trained technician on an inverted Lecia DMI3000 B microscope and QICAM 142 
MicroPublisher 5.0 (MP5.0-RTV-CLR-10, QIMAGING) camera with QCapture software 143 
(Surrey, BC, Canada). Contractile area was quantified using the H&E images by alternatively 144 
density slicing for the hypercontracted cells and necrotic areas, then subtracting that sum 145 
from the total area using Open Lab Software (Improvision).  The density slice function uses 146 
prescribed pixel parameters to select the dark-red, hypercontracted cells and the light pink 147 
necrotic areas. Similarly, fibrotic area was quantified in the entire muscle cross section by 148 
using the density slice function of the Open Lab Software to quantify the blue area of the 149 
trichrome images, which is divided by the total area to identify the percent of the total area 150 
that was fibrotic.  151 
Fiber area distribution was assessed using immunohistochemistry (IHC).  Sections 152 
were incubated with anti-laminin (anti-rabbit, ThermoScientific, RB-082-A) using our 153 
standard IHC protocol as previously described (29). Briefly, after washing (phosphate 154 
buffered saline (PBS)) and blocking (5% goat serum, 5% bovine serum albumin, 1% DMSO 155 
in 2X PBS) slides were incubated in primary antibody (laminin, 1:100 in blocking solution) 156 
overnight at 4°C, then washed and incubated in secondary antibody (anti-rabbit AlexaFluor 157 
488, 1:500, Cell Signaling 4412S) for 1 h at room temperature. Slide covers were mounted 158 
with SlowFade™ Gold Antifade Mountant with DAPI (S36938, ThermoFisher) and sealed 159 
with nail polish.  Slides were imaged at 10x magnification on the same inverted microscope.  160 
For each sample, two independent images were taken and quantified (100-400 fibers/image). 161 
Fiber areas were objectively measured using OpenLab Software. 162 
Statistics.  To determine significant sources of variation in single time point 163 
measures, such as tetanic force, specific force, fiber area distribution, contractile area, and 164 
fibrotic area, one-way ANOVAs were performed using GraphPad Prism with a Newman-165 
Keuls post hoc test. Data from soleus fatigue experiments were analyzed utilizing a repeated 166 
measure model in which a spatial power variance structure was used. EDL contraction 167 
induced injury data were analyzed using a repeated measures model that implemented an 168 
autoregressive variance structure. A mixed model method was used to determine significant 169 
sources of variation (Proc Mixed, SAS V9.0, SAS Inst. Inc., Cary, NC) that included fixed 170 
effects for treatment, time, and treatment×time interaction with pre-treatment value (20 min 171 
baseline measurement at 4 months of age) as a linear covariate. When fixed effects were 172 
significant sources of variation, the PDIFF statement of SAS was used at the fixed effect 173 
level of LS means to separate pairwise differences. 174 
Results 175 
  Animal characteristics. Mouse body mass was decreased by 13-38% in untreated and 176 
treated D2-mdx mice compared to healthy (DBA) mice (p<0.05).  In addition, the 177 
QNRLisPred group was decreased 38% and 28% compared to DBA and D2-mdx (p<0.05), 178 
respectively, and was similar to the remaining treatment groups.  Soleus, extensor digitorum 179 
longus (EDL), gastrocnemii and tibialis anterior (TA) muscles were weighed.  EDL, 180 
gastrocnemius and TA masses were decreased 29-47%, 58-71% and 42-56%, respectively, in 181 
untreated and treated D2-mdx mice compared to muscles from DBA mice (p<0.05). 182 
Interestingly, the soleus was similar between all groups with the exception of D2-mdx mice 183 
treated with QNRLisPred, which was decreased approximately 13% compared to all groups 184 
(p<0.05).  Similarly, the EDLs and gastrocnemius muscles from QNRLisPred were 185 
significantly decreased compared to untreated D2-mdx (p<0.05). Lastly, EDLs from Q-186 
treated D2-mdx mice were 7% greater than untreated D2-mdx (p<0.05). When tissues masses 187 
were normalized to body mass, gastrocnemius and TA masses were decreased in all D2-mdx 188 
groups compared to DBA by 45-53% and 22-35%, respectively (p<0.05). Similarly, D2-mdx 189 
EDL relative mass was decreased by 26% compared to DBA (p<0.05), and treatment with Q 190 
or QNRLis increased muscle mass by 23-29% compared to EDLs from untreated D2-mdx 191 
mice (p<0.05). Lastly, soleus relative mass was increased by 16-32% in treated and untreated 192 
D2-mdx mice compared to DBA (p<0.05) and were similar to each other.  193 
 In vitro muscle function. Muscle function was assessed in the soleus and EDL 194 
following 7 months of treatment (Figures 1 and 2).  Soleus tetanic force and specific tension 195 
were decreased by 32% in D2-mdx compared to DBA (p<0.05) with no effect of treatments 196 
(Figure 1A).  Following 10 sec of a fatigue protocol, force production was similar between 197 
groups, however, following 120 sec QNRLisPred produced 25% greater force than DBA 198 
(p<0.05) mice while DBA and D2-mdx were similar.  Additionally, QNRLisPred produced 199 
28% more force than D2-mdx and DBA following 300 sec of a fatigue protocol that was 200 
maintained through 600 sec of a 1 contraction/sec fatigue protocol (p<0.05; Figure 1C).   201 
In the EDL, tetanic and specific tension were significantly decreased by 50% and 202 
20%, respectively, in D2-mdx groups compared to DBA (Figure 2A&B; p<0.05).  203 
Additionally, EDL tetanic tension was further decreased by 25% in QNRLisPred treated 204 
mice compared to remaining D2-mdx groups (p<0.05). Resistance to contraction-induced 205 
injury was assessed by measuring peak force during five eccentric contractions, in which the 206 
muscles were stretched 10% past Lo. Following contractions 3, 4 and 5, D2-mdx produced 207 
18%, 27% and 36% less force compared to DBA (p<0.05), respectively.  Following 208 
contraction 4, Q, NR, QNR and Lis produced 17-19% less force than DBA (p<0.05).  209 
Similarly, after contraction 5, Q, NR, Lis, QLis and QNRLis-treated groups produced 20-210 
29% less for than DBA (p<0.05).  We noted that Q, NR, Lis, QLis, and QNRLis-treated mice 211 
appeared to produce greater force than untreated D2-mdx mice particularly following 212 
contractions 3-5, however, these numerical changes did not reach statistical significance. 213 
QNRLisPred-treated mice produced 32% more force during the 5th contraction than D2-mdx 214 
and was statistically similar to DBA, suggesting protection from contraction induced injury 215 
(Figure 2B).   216 
Histology. Given that muscle function was largely similar between untreated and 217 
treated D2-mdx mice we performed histopathological examination on groups that showed 218 
therapeutic promise (numerical changes suggestive of therapeutic potential) (Figure 3). 219 
Hence, we assessed histological muscle damage in the DBA, D2-mdx, QLis, QNRLis, and 220 
QNRLisPred groups.  Soleus contractile area decreased from 95% in DBA mice to 221 
approximately 65-73% in D2-mdx, QNRLis, and QNRLisPred (p<0.05).   Surprisingly, 222 
contractile area was only 41% in QLis. In the EDL, contractile area was decreased by 41-223 
64% in D2-mdx groups compared to DBA mice (Figure 3; p<0.05).  Treatment with QNRLis 224 
further decreased contractile area compared to QLis and QNRLisPred.  225 
Given the above findings, secondary analyses were performed on the soleus in order 226 
to gain further insights. Fibrotic area increased from less than 5% in DBA to 11-18% in D2-227 
mdx groups (p<0.05). Treatments did not significantly decrease fibrotic area compared to 228 
D2-mdx, but treatment with QNRLisPred significantly increased fibrotic area compared to 229 
QLis, (Figure 4; p<0.05).   230 
Distribution of fiber cross-sectional area was shifted toward an overabundance of 231 
smaller fibers and a corresponding underrepresentation of larger fibers in D2-mdx groups 232 
compared to DBA (Figure 5A).  The mean fiber area was similar between DBA, D2-mdx and 233 
QLis, but was decreased by 32% in QNRLis and QNRLisPred compared to DBA (Figure 5B; 234 
p<0.05).  Median fiber cross-sectional area was decreased by 20-45% in all D2-mdx groups 235 
compared to DBA (Figure 5B; p<0.05).  Additionally, the variance coefficient was at least 236 
doubled in all D2-mdx groups compared to DBA and increased 19% in QNRLis compared to 237 
D2-mdx (Figure 5B; p<0.05).     238 
Discussion 239 
 DMD is caused by a mutation in the dystrophin gene resulting in the absence of 240 
functional dystrophin protein and a complicated sequela.  Researchers and clinicians continue 241 
to pursue a variety of strategies intended to counter these cellular dysfunctions and slow or 242 
prevent disease progression. While transformative therapies are currently in various phases of 243 
FDA approval to treat tomorrow’s patients, pragmatic solutions are urgently needed to treat 244 
today’s patients.  In this study, our purpose was to determine the extent to which treatment of 245 
D2-mdx mice with quercetin, nicotinamide riboside (NR), and/or Lisinopril (Lis) improved 246 
muscle function and decreased disease-related muscle damage. Counter to our hypotheses, 247 
we failed to demonstrate that treatment with quercetin, NR, or Lisinopril independently or in 248 
combination meaningfully improved muscle function or decreased histopathological injury. 249 
Only a cocktail containing Pred (QNRLisPred) provided some protection to fatigue and 250 
contraction induced injury but did not decrease histological injury.   251 
Consistent with our earlier work using long-term quercetin treatment of mdx mice, a 252 
relatively less severe rodent model of DMD (28), application of quercetin over 7 months to 253 
D2-mdx mice did not correspond to improved limb muscle function. Previously, we 254 
demonstrated that quercetin improved soleus specific force, but did not potentiate other 255 
parameters of muscle function. We then surmised that the transient nature of quercetin-256 
mediated protection (28) may be due to depleted NAD+ and successfully treated with NR 257 
(28). Early support for this rationale was established by prior observations that NAD+ 258 
depletion in mdx mice was corrected following 12 weeks of NR supplementation (25). This 259 
promising outcome was accompanied by an improved exercise capacity despite elevated 260 
energetic stress due to decreased mitochondrial oxidative phosphorylation rate and increased 261 
mitochondrial ATP production load (25). Despite dosing differences in this investigation, it is 262 
likely that the advanced disease progression in the present investigation (older mice, more 263 
severe model) and/or the long-term use of NR limited its efficacy.  Given that 1) the D2-mdx 264 
model more accurately recapitulates injury in humans than the mdx mouse model and 2) 265 
long-term treatment should be expected with DMD patients, the applicability of NR to DMD 266 
seems tenuous based on the current findings.  267 
In the present investigation, Lisinopril did not improve measures of muscle function 268 
nor decrease histological damage. Similarly, short-term treatment with Lisinopril did not 269 
improve muscle function in an mdx/Utrn+/- model, though Lisinopril decreased histological 270 
injury (21).  When used in combination with spironolactone, an aldosterone receptor 271 
antagonist, Lisinopril increased EDL and diaphragm function and decreased histological 272 
injury in the quadriceps when treatment was started at 4 weeks but not at 8 weeks in 273 
mdx/Utrn+/- mice (23). Interestingly, in the mdx model, treatment with Lisinopril and 274 
spironolactone did not improve muscle function nor decrease histological damage (19). 275 
While differences in animal model, duration of study, dose (33 mg/L or 66 mg/L) and use of 276 
drug in combination likely account for some differences between these investigations, 277 
collectively they provide underwhelming support for continued use of Lisinopril, alone, as a 278 
skeletal muscle therapy for DMD.  Notably, the combination of Lisinopril and metoprolol (β-279 
blocker) mitigate some aspects of disease severity in cardiac muscle in a clinical population 280 
(32).  281 
Within the context of preclinical murine experiments to date, DMD has been most 282 
commonly modeled by the C57BL/10-mdx (mdx) mouse. While this mouse model has been 283 
useful for studies related to disease mechanism, its mild phenotype may contribute to 284 
translational limitations of therapeutic findings to human populations. In this study we used 285 
an emerging model of DMD, the DBA/2J-mdx (D2-mdx) mouse, which has a relatively 286 
severe, progressive pathology and early-onset cardiac dysfunction (10). Consistent with our 287 
data from 48-week-old D2-mdx mice, EDL tetanic force and specific force were decreased at 288 
7, 28 and 52 weeks (10). Moreover, similar to our current findings in soleus, increased 289 
fibrosis was previously reported in tibialis anterior, gastrocnemius, and quadriceps in 6- and 290 
8-month-old D2-mdx mice compared to control (15). Interestingly, fat accumulation was 291 
significantly increased at 6 months in the gastrocnemius and at 6 and 8 months in the 292 
quadriceps (15), but in this investigation fatty infiltration was not visually apparent in the 11 293 
month old soleus or EDL. Ostensibly, increased fatty infiltration decreased contractile cross-294 
sectional area is this prior work (15), and support functional observations in the current 295 
investigation. Moreover, as in this investigation, Coley et al. (10) discovered that the 296 
distribution of fiber area was shifted toward a greater frequency of small fibers. These data in 297 
combination with current findings, when paired with decreased muscle mass and findings 298 
from H&E and trichrome analyses, support a reduction in fiber size as well as functional 299 
cross section area of the whole muscle, which translate to dramatic reductions in muscle 300 
function.   301 
In summary, and counter to our study hypotheses, quercetin, nicotinamide riboside, 302 
and Lisinopril (alone and in combination), were not associated with resistance to dystrophic 303 
disease progression in limb muscle. Treatment with QNRLisPred provided partial 304 
improvements in muscle function but did not mitigate other indices of disease progression.  305 
Further, some indices of disease were exacerbated in the QNRLisPred group raising the 306 
possibility of negative interactions of these compounds. Collectively, these data indicate that 307 
quercetin and these quercetin-based cocktails have limited value in the treatment of 308 
dystrophin-deficient limb muscles and alternative approaches should be considered.   309 
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  316 
Table 1. Animal and muscle masses. Body mass was decreased in dystrophic (D2-mdx) 317 
compared to healthy (DBA) mice, and treatment with QNRLisPred further decreased 318 
body mass.  Absolute muscle masses were reduced in dystrophic mice compared to 319 
healthy, except the soleus was similar between groups. Treatment with QNRLisPred 320 
further decreased absolute muscle masses. Similarly, relative muscle masses were 321 
decreased in dystrophic mice, regardless of tissue or treatment, DBA (n=10), D2-mdx 322 
(n=8), Q (n=9), NR (n=8), QNR (n=8), Lis (n=7), QLis (n=10), QNRLis (n=8), and 323 




 DBA D2-mdx Q NR QNR Lis QLis QNRLis QNRLisPred 
Body Mass (g) 39.53 ± 1.81 34.36 ± 1.13* 28.36 ± 1.25*# 29.63 ± 1.14*† 31.18 ± 1.49*† 32.28 ± 1.71*† 31.38 ± 0.76*† 28.92 ± 0.84* 24.57 ± 0.98*# 
Soleus (mg) 7.5 ± 0.2 7.6 ± 0.2 7.1 ± 0.3† 6.9 ± 0.3† 7.1 ± 0.2† 7.2 ± 0.2† 7.5 ± 0.2† 6.9 ± 0.2† 6.0 ± 0.2*#
Rel Soleus (mg/g) 0.19 ± 0.01 0.22 ± 0.01* 0.25 ± 0.01* 0.24 ± 0.01* 0.23 ± 0.01* 0.23 ± 0.01* 0.24 ± 0.01* 0.24 ± 0.01* 0.25 ± 0.01* 
EDL (mg) 8.9 ± 0.1 5.9 ± 0.1* 6.3 ± 0.2*#† 5.7 ± 0.2† 5.9 ± 0.1† 6.0 ± 0.2† 5.9 ± 0.1† 5.9 ± 0.2† 4.7 ± 0.1*#
Rel EDL (mg/g) 0.23 ± 0.01 0.17 ± 0.00* 0.22 ± 0.01# 0.19 ± 0.01* 0.19 ± 0.01* 0.19 ± 0.01* 0.20 ± 0.00* 0.21 ± 0.01# 0.20 ± 0.01* 
Gast (mg) 123.30 ± 2.2 51.30 ± 1.6* 49.43 ± 2.14*† 47.93 ± 1.49*† 46.99 ± 1.36*† 48.26 ± 1.12*† 48.85 ± 1.58*† 46.03 ± 2.03*† 36.29 ± 1.09*# 
Rel Gast (mg/g) 3.17 ± 0.09 1.50 ± 0.05* 1.74 ± 0.06* 1.63 ± 0.06* 1.52 ± 0.06* 1.52 ± 0.07* 1.56 ± 0.05* 1.60 ± 0.08* 1.49 ± 0.05* 
TA (mg) 50.00 ± 3.5 28.40 ± 0.9* 28.24 ± 0.73* 25.83 ± 0.75* 26.73 ± 0.86* 27.33 ± 0.82* 28.87 ± 0.74*† 28.03 ± 0.71* 22.01 ± 0.95*# 




Masses and relative (rel) masses are represented as mean ± SEM. EDL - extensor digitorum longus; Gast - gastrocnemius; TA - 325 
tibialis anterior. *Indicates significantly different from DBA, # indicates significantly different from D2-mdx, and † = significantly 326 




Figure 1. Soleus muscle function. A) Tetanic force and specific force were decreased in D2-331 
mdx mice, regardless of treatment, compared to DBA. B) Resistance to fatigue was measured 332 
over 10 min. C) Despite similar fatigue resistance between DBA and D2-mdx at these time 333 
points, QNRLisPred increased fatigue resistance at 120, 300 and 600 seconds compared to 334 
D2-mdx. DBA (n=10), D2-mdx (n=7-8), Q (n=8), NR (n=8), QNR (n=8), Lis (n=7), QLis 335 
(n=9-10), QNRLis (n=7), and QNRLisPred (n=9).  Statistical significance was established at 336 
p<0.05, * = significantly different from DBA, # = significantly different from D2-mdx. 337 
 338 
Figure 2. Extensor digitorum longus muscle function. A) Tetanic force and specific force 339 
were decreased in D2-mdx mice, regardless of treatment, compared to DBA. QNRLisPred 340 
further decreased tetanic force compared to all groups, but specific tension similar to D2-mdx 341 
groups. B) Resistance to contraction induce injury was decreased in D2-mdx mice. Treatment 342 
with QNRLisPred improved resistance to contraction induced injury following the 5th 343 
contraction. DBA (n=9), D2-mdx (n=7-8), Q (n=8-9), NR (n=8), QNR (n=8), Lis (n=7), QLis 344 
(n=9-10), QNRLis (n=7-8), and QNRLisPred (n=9).  Statistical significance was established 345 
at p<0.05, * = significantly different from DBA, # = significantly different from D2-mdx, ‡ = 346 
significantly different from all other D2-mdx groups. 347 
 348 
Figure 3. H&E staining of soleus and EDL. A) Representative H&E images (40X) of 349 
soleus muscle and quantification of contractile area. B) Representative H&E images (40X) of 350 
EDL and quantification of contractile area. Contractile area was significantly decreased in 351 
D2-mdx mice, which was not corrected by these treatments. DBA (n=8-9), D2-mdx (n=8), 352 
 
 
QLis (n=10), QNRLis (n=7-9), and QNRLisPred (n=8).  Statistical significance was 353 
established at p<0.05, * = significantly different from DBA, # = significantly different from 354 
D2-mdx, † = significantly different from QLis, ‡ = significantly different from QNRLis. 355 
 356 
Figure 4. Trichrome staining of the soleus. Representative trichrome images (40X) of 357 
soleus muscle and quantification of fibrotic area. Fibrotic area was increased in dystrophic 358 
muscle. DBA (n=9), D2-mdx (n=8), QLis (n=10), QNRLis (n=8), and QNRLisPred (n=8).  359 
Statistical significance was established at p<0.05, * = significantly different from DBA, † = 360 
significantly different from QLis. 361 
 362 
Figure 5. Fiber area distribution of the soleus. A) Dystrophic fiber area distribution was 363 
shifted towards an abundance of small fibers. B) Mean fiber area was similar between health 364 
and dystrophic muscle, but median was decreased in all D2-mdx groups. Additionally, the 365 
variance coefficient was elevated in dystrophic muscle, regardless of treatment.  C) 366 
Representative IHC images (10X) of laminin of soleus muscle. DBA (n=8), D2-mdx (n=7), 367 
QLis (n=7), QNRLis (n=4), and QNRLisPred (n=5). Groups were compared within each 368 
fiber area bin using a one-way ANOVA. Significance was established at p<0.05, * = 369 
significantly different from DBA, # = significantly different from D2-mdx, † = significantly 370 
different from QLis. 371 
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